

M03: Peripheral Blood Leukocyte Cell Differential

Study Number: I16011

Test Compound: 2-((1-(4-Phenoxyphenoxy)propan-2-yl)oxy)pyridine

Date: 30 Aug 2024

DTTID: 106-012-003-000-3

CAS Number: 95737-68-1

Time: 10:38:14 AM

Study Type: Immune screening

DTXSID: DTXSID1032640

Species/Strain: Rat/Harlan Sprague Dawley

Females: Immunopathology

	Treatment Groups					
	0 mg/kg	62.5 mg/kg	125 mg/kg	250 mg/kg	500 mg/kg	15 mg/kg CPS
Leukocytes (x10 ³ /μL)	10.116 ± 0.666[12]	10.537 ± 0.613[12]	11.626 ± 0.836[12]	10.868 ± 0.955[11]	10.591 ± 0.658[12]	2.693 ± 0.238[8]**
Absolute counts						
Lymphocytes (x10 ³ /μL)	8.625 ± 0.629[12]	9.105 ± 0.564[12]	9.993 ± 0.780[11]	9.295 ± 0.800[11]	9.194 ± 0.546[12]	1.999 ± 0.253[8]**
Neutrophils (x10 ³ /μL)	0.993 ± 0.085[12]	0.888 ± 0.055[12]	0.917 ± 0.103[11]	0.978 ± 0.115[11]	0.889 ± 0.118[12]	0.455 ± 0.063[8]**
Monocytes (x10 ³ /μL)	0.195 ± 0.025[12]	0.211 ± 0.021[12]	0.247 ± 0.031[11]	0.246 ± 0.038[11]	0.237 ± 0.026[12]	0.053 ± 0.006[8]**
Eosinophils (x10 ³ /μL)	0.108 ± 0.010[12]**	0.130 ± 0.011[12]	0.096 ± 0.012[11]	0.111 ± 0.012[11]	0.066 ± 0.006[12]**	0.110 ± 0.039[8]
Basophils (x10 ³ /μL)	0.093 ± 0.011[12]	0.094 ± 0.011[12]	0.104 ± 0.015[11]	0.117 ± 0.020[11]	0.092 ± 0.009[12]	0.025 ± 0.007[8]**
Large Unstained Cells (x10 ³ /μL)	0.101 ± 0.014[12]	0.108 ± 0.017[12]	0.116 ± 0.018[11]	0.122 ± 0.026[11]	0.109 ± 0.015[12]	0.049 ± 0.016[8]*
Relative counts						
Percent Lymphocytes (%)	84.80 ± 1.08[12]	86.25 ± 0.61[12]	87.05 ± 0.55[11]	85.74 ± 0.91[11]	87.13 ± 0.93[12]	72.34 ± 5.21[8]**
Percent Neutrophils (%)	10.28 ± 1.01[12]	8.59 ± 0.59[12]	8.05 ± 0.58[11]	8.90 ± 0.48[11]	8.17 ± 0.86[12]	18.05 ± 3.38[8]*
Percent Monocytes (%)	1.88 ± 0.16[12]	2.05 ± 0.19[12]	2.17 ± 0.25[11]	2.25 ± 0.25[11]	2.22 ± 0.19[12]	1.98 ± 0.21[8]
Percent Eosinophils (%)	1.18 ± 0.22[12]**	1.28 ± 0.12[12]	0.88 ± 0.13[11]	1.07 ± 0.13[11]	0.63 ± 0.05[12]**	5.01 ± 2.20[8]**
Percent Basophils (%)	0.90 ± 0.08[12]	0.88 ± 0.06[12]	0.85 ± 0.05[11]	1.01 ± 0.09[11]	0.87 ± 0.04[12]	0.94 ± 0.14[8]
Percent Large Unstained Cells (%)	0.94 ± 0.11[12]	0.98 ± 0.11[12]	0.98 ± 0.09[11]	1.05 ± 0.15[11]	1.00 ± 0.10[12]	1.68 ± 0.43[8]

M03: Peripheral Blood Leukocyte Cell Differential

Study Number: I16011

DTTID: 106-012-003-000-3

Study Type: Immune screening

Species/Strain: Rat/Harlan Sprague Dawley

Test Compound: 2-((1-(4-Phenoxyphenoxy)propan-2-yl)oxy)pyridine

CAS Number: 95737-68-1

DTXSID: DTXSID1032640

Date: 30 Aug 2024

Time: 10:38:14 AM

LEGEND

Data are displayed as mean \pm SEM (N) unless otherwise noted.

Statistical analysis performed by Jonckheere (trend) and Shirley or Dunn (pairwise) tests. The positive control group (15 mg/kg CPS) was excluded from trend test.

Statistical analysis for the positive control group (15 mg/kg CPS) compared to the vehicle control group was performed using the Wilcoxon rank sum test.

Statistical significance for the control group indicates a significant trend test.

Statistical significance for a treatment group indicates a significant pairwise test compared to the vehicle control group.

* Statistically significant at $P \leq 0.05$

** Statistically significant at $P \leq 0.01$

SEM = Standard Error of the Mean

SD = Study Day

CPS = Cyclophosphamide

Females from the vehicle control and treatment groups were removed on SD 28.

**** END OF REPORT ****